Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
Lantern Pharma reported Q1 2026 results with a net loss of $3.3 million, down 27% year-over-year, driven by a 47% reduction in R&D spend to $1.7 million. The company closed a $4.4 million registered direct offering on May 14, 2026, bringing pro forma liquidity to approximately $10.7 million, which management expects to fund operations into mid-Q1 2027. Strategically, Lantern launched withZeta.ai, its multi-agentic AI co-scientist platform, and announced a plan to spin it out into an independent entity to unlock separate valuation and funding.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Drug Name
- LP-300, LP-184, LP-284, STAR-001
- Guidance
- Pro forma liquidity expected to fund operations into the middle of the first quarter of 2027
- Revenue Yoy
- 0
- Deal Value Usd
- 4400000
- Phase Of Trial
- Phase 2 (LP-300), Phase 1 (STAR-001, LP-284)
- Offering Price
- 0
- Shares Offered
- 1454175
- Net loss
- 3300000
- Ga expense
- 1700000
- Rd expense
- 1700000
- Net loss yoy change
- -27%
- Pre funded warrants
- 681748
- Cash and equivalents
- 6300000
- Warrants outstanding
- 2135923
- Rd expense yoy change
- -47%
- Warrants exercise price
- 2.27
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.